Ziopharm Oncology (ZIOP) executives are pitching a turnaround strategy, claiming that recently enacted changes are freeing the struggling biotech to finally make good on past promises to develop new cancer immunotherapies.

So far, the “new” Ziopharm story seems to be resonating with investors. The company’s stock price bottomed out at just under $2 per share in late October. Since then, the stock is up 75 percent. Is this recent investor optimism in Ziopharm justified? Let’s take a closer look.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy